| 背景 | This is a bulk-format mouse monoclonal antibody (clone 2D5-1.9, IgG2a kappa) raised against human Hepsin. It is validated for ELISA, flow cytometry, and Western blot, making it suited to characterizing Hepsin expression on human cells and in lysates. The antibody is offered as a low-endotoxin, research-grade (RUO) preparation available in bulk milligram-to-gram quantities, which supports large or repeated in-vitro experiments, assay development, and screening workflows where lot consistency and material supply matter. As a mouse IgG2a kappa reagent it pairs with standard anti-mouse IgG2a secondary detection systems and isotype controls. Because the target is human and this is a bulk research antibody rather than an in-vivo functional depleting or blocking reagent, it is intended for cell-based, biochemical, and immunoassay applications rather than mouse dosing studies. Its defined clone, isotype, and multi-application validation make it a practical choice for laboratories studying Hepsin biology, protease activity, and expression in human cancer and epithelial systems.
Hepsin (TMPRSS1; gene HPN, UniProt P05981) is a type II transmembrane serine protease anchored at the cell surface via an N-terminal transmembrane domain, with an extracellular scavenger-receptor cysteine-rich region and a C-terminal chymotrypsin-like catalytic serine protease domain. It is normally expressed in the liver and at lower levels in kidney, thyroid, and other epithelia. Hepsin activates several substrates implicated in cell signaling and matrix remodeling, including pro-hepatocyte growth factor (pro-HGF), pro-urokinase, and components involved in basement membrane integrity, and it has been linked to hepatocyte growth and metabolic regulation. Hepsin is markedly overexpressed in prostate cancer and in other carcinomas, where its proteolytic activity is associated with disrupted epithelial architecture, invasion, and metastasis. These features make Hepsin a target of interest for cancer biomarker studies and for the development of protease inhibitors. Hepsin is expressed on the surface of epithelial cells including the liver, kidney, prostate, and thyroid in human tissues. |
|---|
